Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-09-05
1999-10-05
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
A61K 31235
Patent
active
059625228
ABSTRACT:
A method for increasing bioavailability of an orally administered pharmaceutical compound comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with propyl gallate. Improved formulations of pharmaceutical compounds include propyl gallate to enhance the bioavailability of the active ingredient of the pharmaceutical compound.
REFERENCES:
patent: 4310543 (1982-01-01), Gallo-Torres
patent: 5156842 (1992-10-01), Mulligan
patent: 5567592 (1996-10-01), Benet et al.
patent: 5665386 (1997-09-01), Benet et al.
Bonkovsky et al., "Cytochrome P.sub.450 of Small Intestinal Epithelial Cells," Gastroenterology, 88:458-467 (1985).
Bradford, M.M. "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding." Anal. Biochem. 72:248-254 (1976).
Fabre, G., et al., Evidence of CYP3A-mediated N-deethylation of aminodarone in human liver microsomal fractions, Drug Metabolism and Disposition, 21(6):978-985 (1993).
Fasco et al., "Rat Small Intestinal Cytochromes P450 Probed by Warfarin Metabolism" Mol. Pharmacol., 43:226-233 (1993).
Greenblatt, David J., "Presystemic Extraction: Mechanisms and Consequences," J. Clin. Pharmcol., 33:650-656 (1993).
Gonzalez et al., Human P450PCN1: Sequence, Chromosome Localization, and Direct Evidence through cDNA Expression that P450PCN1 is Nifedipine Oxidase, DNA, 7(2):79-86 (1988).
Kaminsky et al., "Small Intestinal Cytochromes P450," Toxicology, 21(6):407-422 (1992).
Kivisto et al., "Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole," Clinical Pharmacology & Therapeutics, 62(3):348-354 (1997).
Kolars, J.C. et al., "Identification of Rifampin-Inducible P450IIIA4 (CYP3A4) in Human Small Bowel Enterocytes," J. Clin. Investig., 90:1871-1878 (1992).
Kolars et al., "Heterogeneity of Cytochrome P450IIIA Expression in Rat Gut Epithelia," Gastroenterology, 102:1188-1198 (1992).
Komori et al., "Cytochrome P-450 in Human Liver Microsomes: High-Performance Liquid Chromatographic Isolation of Three Forms and Their Characterization," J. Biochem., 104:912-16 (1988).
Kronbach et al., "Cyclosporine Metabolism in Human Liver: Identification of a Cytochrome P-450III Gene Family as the Major Cyclosporine-Metabolizing Enzyme Explains Interactions of Cyclosprine with Other Drugs," Clin. Pharmacol. Ther., 43(6):630-5 (1988).
Nash, "The Colorimetic Estimation of Formaldehyde by Means of the Hantzach Reaction," Biochem. J., 55:416-421 (1953).
Schmiedlin-Ren et al., "Cultured Adult Rat Jejunal Explants as a Model for Studying Regulation of CYP3A," Biochem. Pharmacol., 46(5):905-918 (1993).
Somberg et al., "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the 1990's," J. Clin. Pharmcol., 33:670-673 (1993).
Tam, Yun K., "Individual Variation in First-Pass Metabolism," Clin. Pharmacokinet, 25(4):300-328 (1993).
Trivier et al., "Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report)," Life Sci., 52:PL91-96 (1993).
van Hoogdalem et al., "Intestinal Drug Absorbtion Enhancement: An Overview," Pharmacol. Ther., 44:407-443 (1989).
Watkins et al., "Identification of Glucocorticoid-Inducible Cytochromes P-450 in the Intestinal Mucosa of Rats and Man," J. Clin. Invest., vol. 80:1029-36 (1987).
Watkins et al., "The Role of Cytochromes P-450 in Cyclosporine Metabolism," J. Am. Acad. Dermacol., 23:1301-1309 (1990).
Watkins et al., "Drug Metabolism by Cytochromes P450 in the Liver and Small Bowel," Gastrointestinal Pharmacology, 21(3):511-527 (1992).
WHO Food Additives Series, vol. 32:3-23 (1993), Abstract.
Wrighton et al., "Demonstration in Multiple Species of Inducible Hepatic Cytochromes P-450 and their mRNAs Related to the Glucocorticoid-Inducible Cytochrome P-450 of the Rat," Molecular Pharmacology, 28:312-321 (1985).
Wrighton et al., "Studies on the Expression and Metabolic Capabilities of Human Liver Cytochrome P450IIIA5 (HLp3)," Molec. Pharmacol., 38:207-213 (1990).
Wu et al., "Use of IV and Oral Drug Levels from Cyclosporine (CsA) with Concomitant Rifampin to Differentiate Gut Absorption and Metabolism," Pharm. Res. 10 (1993) Abstract # PPDM 8185,
Yang et al., "Inhibition of Hepatic Mixed Function Oxidase Activity by Propyl Gallate," Biochemical Pharmacology, 23:3129-3138 (1974).
Kelleher, J., et al., Modification of Paracetamol Hepatotoxicity by Anti-Oxidants, J. Ind. Med. Res., 4 suppl. (4):138-144 (1976).
Kelleher, J., et al., Modification of Paracetamol Toxicity by Antioxidants, Biochem. Soc. Transact., 4:292-294 (1976).
Kedderis, G. L., et al., "N-Demethylation Reactions Catalyzed by Chloroperoxides," J. Biol. Chem., 255(21):10174-82 (1980).
Kedderis, G. L., et al., "Characterization of the N-Demethylation Reactions Catalyzed by Chloroperoxidase," Microsomes, Drug Oxid., Chem. Carcinog., Int. Symp. Microsomes Drug Oxid., 1:351-4, pub. Academic Press, eds. Coon, et al. (1980).
Bamforth, K. J., et al., "Common Food Additives are Potent Inhibitors of Humal Liver 17.alpha.-Ethinyloestradiol and Dopamine Sulphotransferases," Biochemical Pharmacology, 46(10):1713-1720 (1993).
Weinke, S., et al., "Effect of Four Synthetic Antioxidants on the Formation of Ethylene from Methional in Rat Liver Microsomes," Toxicology Letters, 35:247-251 (1987).
Benet Leslie Z.
Wacher Vincent J.
AvMax, Inc.
Spivack Phyllis G.
LandOfFree
Propyl gallate to increase bioavailability of orally administere does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Propyl gallate to increase bioavailability of orally administere, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Propyl gallate to increase bioavailability of orally administere will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1172159